Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2010, Article ID 749579, 11 pages
http://dx.doi.org/10.1155/2010/749579
Review Article

Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?

1Department of Clinical Therapeutics, “Alexandra” Hospital, School of Medicine, University of Athens, Athens, Greece
2Oncology Centre, Castle Hill Hospital, Hull and East Yorkshire NHS Trust, Cottingham, UK

Received 27 September 2009; Accepted 8 December 2009

Academic Editor: Paul J. Hoskins

Copyright © 2010 Flora Zagouri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, F. Bray, P. Pisani, and D. M. Parkin, GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC Cancer Base no. 5, IARC Press, Lyon, France, 2004, version 2.0.
  2. G. F. Fleming, “Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant,” Journal of Clinical Oncology, vol. 25, no. 20, pp. 2983–2990, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. R. M. Kelley and W. H. Baker, “Progestational agents in the treatment of carcinoma of the endometrium,” The New England Journal of Medicine, vol. 264, pp. 216–222, 1961. View at Google Scholar · View at Scopus
  4. S. B. Decruze and J. A. Green, “Hormone therapy in advanced and recurrent endometrial cancer: a systematic review,” International Journal of Gynecological Cancer, vol. 17, no. 5, pp. 964–978, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. Markman, “Hormonal therapy of endometrial cancer,” European Journal of Cancer, vol. 41, no. 5, pp. 673–675, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. T. Thigpen, J. Blessing, P. DiSaia et al., “Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels—The Gynecologic Oncology Group experience,” in Endocrinology and Malignancy, E. Baulier, S. Iacobelli, and W. McGuire, Eds., pp. 446–454, Parthenon, Pearl River, NY, USA, 1986. View at Google Scholar
  7. J. T. Thigpen, M. F. Brady, R. D. Alvarez et al., “Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group,” Journal of Clinical Oncology, vol. 17, no. 6, pp. 1736–1744, 1999. View at Google Scholar · View at Scopus
  8. S. S. Lentz, M. F. Brady, F. J. Major, G. C. Reid, and J. T. Soper, “High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 14, no. 2, pp. 357–361, 1996. View at Google Scholar · View at Scopus
  9. G. M. Rendina, C. Donadio, and M. Fabri, “Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 17, no. 4, pp. 285–291, 1984. View at Google Scholar · View at Scopus
  10. T. Thigpen, M. F. Brady, H. D. Homesley, J. T. Soper, and J. Bell, “Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 19, no. 2, pp. 364–367, 2001. View at Google Scholar · View at Scopus
  11. J. A. Carlson Jr., J. C. Allegra, T. G. Day Jr., and J. L. Wittliff, “Tamoxifen and endometrial carcinoma: alterations in estrogen and progesterone receptors in untreated patients and combination hormonal therapy in advanced neoplasia,” American Journal of Obstetrics and Gynecology, vol. 149, no. 2, pp. 149–153, 1984. View at Google Scholar · View at Scopus
  12. K. J. Pandya, B. Y. Yeap, L. M. Weiner et al., “Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882),” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 24, no. 1, pp. 43–46, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. C. W. Whitney, V. L. Brunetto, R. J. Zaino et al., “Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 92, no. 1, pp. 4–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. D. S. McMeekin, A. Gordon, J. Fowler et al., “A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer,” Gynecologic Oncology, vol. 90, no. 1, pp. 64–69, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. C. E. Humber, J. F. Tierney, R. P. Symonds et al., “Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration,” Annals of Oncology, vol. 18, no. 3, pp. 409–420, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. S. Carey, C. Gawlik, M. Fung-Kee-Fung, A. Chambers, and T. Oliver, “Systematic review of systemic therapy for advanced or recurrent endometrial cancer,” Gynecologic Oncology, vol. 101, no. 1, pp. 158–167, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. T. Thigpen, J. A. Blessing, P. J. DiSaia, E. Yordan, L. F. Carson, and C. Evers, “A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study,” Journal of Clinical Oncology, vol. 12, no. 7, pp. 1408–1414, 1994. View at Google Scholar · View at Scopus
  18. J. T. Thigpen, M. F. Brady, H. D. Homesley et al., “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 22, no. 19, pp. 3902–3908, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. S. Aapro, F. H. van Wijk, G. Bolis et al., “Doxurubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group,” Annals of Oncology, vol. 14, no. 3, pp. 441–448, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. M. A. Dimopoulos, C. A. Papadimitriou, V. Georgoulias et al., “Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study,” Gynecologic Oncology, vol. 78, no. 1, pp. 52–57, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. P. J. Hoskins, K. D. Swenerton, J. A. Pike et al., “Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study,” Journal of Clinical Oncology, vol. 19, no. 20, pp. 4048–4053, 2001. View at Google Scholar · View at Scopus
  22. D. Pectasides, N. Xiros, G. Papaxoinis et al., “Carboplatin and paclitaxel in advanced or metastatic endometrial cancer,” Gynecologic Oncology, vol. 109, no. 2, pp. 250–254, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. H. D. Homesley, J. A. Blessing, J. Sorosky, G. Reid, and K. Y. Look, “Phase II trial of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study,” Gynecologic Oncology, vol. 98, no. 2, pp. 294–298, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. A. du Bois, J. Pfisterer, N. Burchardi et al., “Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut),” Gynecologic Oncology, vol. 107, no. 3, pp. 518–525, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. S. Pignata, G. Scambia, C. Pisano et al., “A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group,” British Journal of Cancer, vol. 96, no. 11, pp. 1639–1643, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. A. Lissoni, A. Gabriele, G. Gorga et al., “Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma,” Annals of Oncology, vol. 8, no. 10, pp. 969–972, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. C. A. Papadimitriou, D. Bafaloukos, G. Bozas et al., “Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study,” Gynecologic Oncology, vol. 110, no. 1, pp. 87–92, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. A. Papadimitriou, G. Fountzilas, D. Bafaloukos et al., “Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study,” Gynecologic Oncology, vol. 111, no. 1, pp. 27–34, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. G. F. Fleming, V. L. Brunetto, D. Cella et al., “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study,” Journal of Clinical Oncology, vol. 22, no. 11, pp. 2159–2166, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. S. Piver, S. B. Lele, B. Patsner, and L. J. Emrich, “Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma,” Obstetrics and Gynecology, vol. 67, no. 2, pp. 261–264, 1986. View at Google Scholar · View at Scopus
  31. T. L. Cornelison, T. R. Baker, M. S. Piver, and D. L. Driscoll, “Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5- fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma,” Gynecologic Oncology, vol. 59, no. 2, pp. 243–248, 1995. View at Publisher · View at Google Scholar · View at Scopus
  32. M. F. Fung, G. V. Krepart, R. J. Lotocki, and M. Heywood, “Treatment of recurrent and metastatic adenocarcinoma of the endometrium with cisplatin, doxorubicin, cyclophosphamide, and medroxyprogesterone acetate,” Obstetrics and Gynecology, vol. 78, no. 6, pp. 1033–1038, 1991. View at Google Scholar · View at Scopus
  33. D. Bafaloukos, G. Aravantinos, G. Samonis et al., “Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: a Hellenic Cooperative Oncology Group study,” Oncology, vol. 56, no. 3, pp. 198–201, 1999. View at Google Scholar · View at Scopus
  34. J. Ayoub, P. Audet-Lapointe, Y. Methot et al., “Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status,” Gynecologic Oncology, vol. 31, no. 2, pp. 327–337, 1988. View at Google Scholar · View at Scopus
  35. G. F. Fleming, V. L. Filiaci, R. C. Bentley et al., “Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study,” Annals of Oncology, vol. 15, no. 8, pp. 1173–1178, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. G. Mountzios, A. Bamias, Z. Voulgaris et al., “Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model,” Gynecologic Oncology, vol. 108, no. 1, pp. 130–135, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. H. D. Homesley, N. P. Meltzer, L. Nieves, L. Vaccarello, G. S. Lowendowski, and A. A. Elbendary, “A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer,” International Journal of Clinical Oncology, vol. 13, no. 1, pp. 62–65, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. S. Lincoln, J. A. Blessing, R. B. Lee, and T. F. Rocereto, “Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 88, no. 3, pp. 277–281, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Lissoni, G. Zanetta, G. Losa, A. Gabriele, G. Parma, and C. Mangioni, “Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer,” Annals of Oncology, vol. 7, no. 8, pp. 861–863, 1996. View at Google Scholar · View at Scopus
  40. M. Mazgani, N. Le, and P. J. Hoskins, “Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer-the British Columbia Cancer Agency experience,” Gynecologic Oncology, vol. 111, no. 3, pp. 474–477, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. C. L. Creutzberg, W. L. J. van Putten, P. C. M. Koper et al., “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial,” The Lancet, vol. 355, no. 9213, pp. 1404–1411, 2000. View at Google Scholar · View at Scopus
  42. J. D. Sears, K. M. Greven, H. M. Hoen, and M. E. Randall, “Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer,” Cancer, vol. 74, no. 4, pp. 1303–1308, 1994. View at Publisher · View at Google Scholar · View at Scopus
  43. H. M. Keys, J. A. Roberts, V. L. Brunetto et al., “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 92, no. 3, pp. 744–751, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. W. Creasman, F. Odicino, P. Maisonneuve et al., “Carcinoma of the corpus uteri,” International Journal of Gynecology and Obstetrics, vol. 95, supplement 1, pp. S105–S143, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. W. T. Creasman, M. F. Kohler, F. Odicino, P. Maisonneuve, and P. Boyle, “Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium,” Gynecologic Oncology, vol. 95, no. 3, pp. 593–596, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. C. L. Creutzberg, W. L. J. van Putten, C. C. Warlain-Rodenhtiis et al., “Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial,” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1234–1241, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. G. von Minckwitz, S. Loibl, K. Brunnert et al., “Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer—a multicentre, open, controlled, prospectively randomised trial,” European Journal of Cancer, vol. 38, no. 17, pp. 2265–2271, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. P. L. Martin-Hirsch, G. Jarvis, H. Kitchener, and R. Lilford, “Progestagens for endometrial cancer,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD001040, 2000. View at Google Scholar · View at Scopus
  49. M. E. Randall, V. L. Filiaci, H. Muss et al., “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 36–44, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. R. Maggi, A. Lissoni, F. Spina et al., “Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial,” British Journal of Cancer, vol. 95, no. 3, pp. 266–271, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. T. Kuoppala, J. Maenpaa, E. Tomas et al., “Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy,” Gynecologic Oncology, vol. 110, no. 2, pp. 190–195, 2008. View at Publisher · View at Google Scholar · View at PubMed
  52. N. Susumu, S. Sagae, Y. Udagawa et al., “Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at PubMed
  53. T. Hogberg, P. Rosenberg, G. Kristensen et al., “A randomized phase-III study on adjuvant treatment with radiation (RT) {+/} chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991),” Journal of Clinical Oncology, vol. 25, p. 5503, 2007. View at Google Scholar
  54. K. Greven, K. Winter, K. Underhill, J. Fontenesci, J. Cooper, and T. Burke, “Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer,” Gynecologic Oncology, vol. 103, no. 1, pp. 155–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. M. A. Sovak, M. L. Hensley, J. Dupont et al., “Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study,” Gynecologic Oncology, vol. 103, no. 2, pp. 451–457, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. H. D. Homesley, V. Filiaci, S. K. Gibbons et al., “A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 112, no. 3, pp. 543–552, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. C. S. Dietrich III, S. C. Modesitt, P. D. Depriest et al., “The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC),” Gynecologic Oncology, vol. 99, no. 3, pp. 557–563, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. C. A. Hamilton, M. K. Cheung, K. Osann et al., “The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma,” Gynecologic Oncology, vol. 103, no. 2, pp. 679–683, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. G. Kelly, D. M. O'Malley, P. Hui et al., “Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy,” Gynecologic Oncology, vol. 98, no. 3, pp. 353–359, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. J. S. H. Low, E. H. Wong, H. S. K. Tan et al., “Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma,” Gynecologic Oncology, vol. 97, no. 1, pp. 171–177, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. K. M. Zanotti, J. L. Belinson, A. W. Kennedy, K. D. Webster, and M. Markman, “The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma,” Gynecologic Oncology, vol. 74, no. 2, pp. 272–277, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. A. L. Fields, M. H. Einstein, A. P. Novetsky, J. Gebb, and G. L. Goldberg, “Pilot phase II trial of radiation “sandwiched” between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC),” Gynecologic Oncology, vol. 108, no. 1, pp. 201–206, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. Y. Aoki, M. Watanabe, T. Amikura et al., “Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer,” Gynecologic Oncology, vol. 94, no. 2, pp. 333–339, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. T. Pustilnik and T. W. Burke, “Adjuvant chemotherapy for high-risk endometrial cancer,” Seminars in Radiation Oncology, vol. 10, no. 1, pp. 23–28, 2000. View at Google Scholar · View at Scopus
  65. T. W. Burke, D. M. Gershenson, M. Morris et al., “Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma,” Gynecologic Oncology, vol. 55, no. 1, pp. 47–50, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. C. A. Stringer, D. M. Gershenson, T. W. Burke, C. L. Edwards, A. N. Gordon, and J. T. Wharton, “Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis,” Gynecologic Oncology, vol. 38, no. 3, pp. 305–308, 1990. View at Publisher · View at Google Scholar · View at Scopus
  67. G. T. Bozas, A. Bamias, E. Kastritis et al., “Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus,” European Journal of Gynaecological Oncology, vol. 26, no. 6, pp. 627–631, 2005. View at Google Scholar · View at Scopus
  68. J. H. Edmonson, J. E. Krook, and J. F. Hilton, “Randomized Phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma,” Gynecologic Oncology, vol. 28, no. 1, pp. 20–24, 1987. View at Google Scholar · View at Scopus
  69. S. Kounelis, N. Kapranos, E. Kouri, D. Coppola, H. Papadaki, and M. W. Jones, “Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature,” Modern Pathology, vol. 13, no. 4, pp. 379–388, 2000. View at Google Scholar · View at Scopus
  70. S. F. Lax, E. S. Pizer, B. M. Ronnett, and R. J. Kurman, “Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression,” Human Pathology, vol. 29, no. 6, pp. 551–558, 1998. View at Publisher · View at Google Scholar · View at Scopus
  71. F. Darvishian, A. J. Hummer, H. T. Thaler et al., “Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases,” American Journal of Surgical Pathology, vol. 28, no. 12, pp. 1568–1578, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. G. E. Konecny, L. Santos, B. Winterhoff et al., “HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer,” British Journal of Cancer, vol. 100, no. 1, pp. 89–95, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. J. V. Bokhman, “Two pathogenetic types of endometrial carcinoma,” Gynecologic Oncology, vol. 15, no. 1, pp. 10–17, 1983. View at Google Scholar · View at Scopus
  74. J. Prat, “Prognostic parameters of endometrial carcinoma,” Human Pathology, vol. 35, no. 6, pp. 649–662, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. J. L. Hecht and G. L. Mutter, “Molecular and pathologic aspects of endometrial carcinogenesis,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4783–4791, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. N. Bansal, V. Yendluri, and R. M. Wenham, “The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies,” Cancer Control, vol. 16, no. 1, pp. 8–13, 2009. View at Google Scholar · View at Scopus
  77. L. K. Mell, J. J. Meyer, M. Tretiakova et al., “Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer,” Clinical Cancer Research, vol. 10, no. 16, pp. 5546–5553, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. G. Moreno-Bueno, D. Hardisson, D. Sarrio et al., “Abnormalities of E- and P-cadherin and catenin (β-, γ-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia,” Journal of Pathology, vol. 199, no. 4, pp. 471–478, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. L. Jia, Y. Liu, X. Yi et al., “Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma,” Clinical Cancer Research, vol. 14, no. 8, pp. 2263–2269, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. S. M. Temkin and G. Fleming, “Current treatment of metastatic endometrial cancer,” Cancer Control, vol. 16, no. 1, pp. 38–45, 2009. View at Google Scholar · View at Scopus
  81. G. L. Mutter, M.-C. Lin, J. T. Fitzgerald et al., “Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers,” Journal of the National Cancer Institute, vol. 92, no. 11, pp. 924–930, 2000. View at Google Scholar · View at Scopus
  82. M. C. Boruban, K. Altundag, G. S. Kilic, and J. Blankstein, “From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures,” European Journal of Cancer Prevention, vol. 17, no. 2, pp. 133–138, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. K. Oda, D. Stokoe, Y. Taketani, and F. McCormick, “High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma,” Cancer Research, vol. 65, no. 23, pp. 10669–10673, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. K. Kurose, X.-P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, and C. Eng, “Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas,” American Journal of Pathology, vol. 158, no. 6, pp. 2097–2106, 2001. View at Google Scholar · View at Scopus
  85. J. B. Basil, P. J. Goodfellow, J. S. Rader, D. G. Mutch, and T. J. Herzog, “Clinical significance of microsatellite instability in endometrial carcinoma,” Cancer, vol. 89, no. 8, pp. 1758–1764, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. S. F. Lax, B. Kendall, H. Tashiro, R. J. C. Slebos, and L. H. Ellenson, “The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways,” Cancer, vol. 88, no. 4, pp. 814–824, 2000. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Saegusa, M. Hashimura, T. Yoshida, and I. Okayasu, “β-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis,” British Journal of Cancer, vol. 84, no. 2, pp. 209–217, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. C. Bilbao, G. Rodríguez, R. Ramírez et al., “The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer,” International Journal of Cancer, vol. 119, no. 3, pp. 563–570, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. A. Doll, M. Abal, M. Rigau et al., “Novel molecular profiles of endometrial cancer-new light through old windows,” Journal of Steroid Biochemistry and Molecular Biology, vol. 108, no. 3-5, pp. 221–229, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. G. Moreno-Bueno, D. Hardisson, C. Sánchez et al., “Abnormalities of the APC/β-catenin pathway in endometrial cancer,” Oncogene, vol. 21, no. 52, pp. 7981–7990, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. S. C. Hye, W. Hu, and J. J. Kavanagh, “Targeted therapies in gynecologic cancers,” Current Cancer Drug Targets, vol. 6, no. 4, pp. 333–363, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. A. M. Oza, L. Elit, J. Biagi et al., “Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer—NCIC IND 160,” Journal of Clinical Oncology, vol. 24, no. 18S, p. 3003, 2006, ASCO Annual Meeting Proceedings (Post-Meeting Edition). View at Google Scholar
  93. B. M. Slomovitz, T. Murke, K. H. Lu et al., “Loss of PTEN expression associated with response to RAD001 (mTor inhibitor) in patients with recurrent endometrial cancer: translational evaluation from a phase II study,” in Proceedings of the 38th Annual Meeting Society of Gynecologic Oncologists, vol. 104, p. 70, San Diego, Calif, USA, March 2007.
  94. N. Colombo, S. McMeekin, P. Schwartz et al., “A phase II trial of the mTor inhibitor AP23573 as a single agent in advanced endometrial cancer,” Journal of Clinical Oncology, vol. 25, no. 18S, p. 5516, 2007, ASCO Annual Meeting Proceedings. Part I. View at Google Scholar
  95. B. M. Slomovitz, K. H. Lu, T. Johnston et al., “A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC),” Journal of Clinical Oncology, vol. 26, p. 5502, 2008, meeting abstracts. View at Google Scholar
  96. A. M. Oza, L. Elit, D. Provencher et al., “A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b,” Journal of Clinical Oncology, vol. 26, 2008, ASCO Annual Meeting Proceedings (Post-Meeting Edition). View at Google Scholar
  97. V. L. Bae-Jump, C. Zhou, J. F. Boggess et al., “The effect of rapamycin on progesterone receptor and estrogen receptor expression in endometrial cancer cells,” in Proceedings of the 39th Annual Meeting Society of Gynecologic Oncologists, vol. 108, p. 168, Tampa, Fla, USA, March 2009.
  98. KK. Leslie, L. Laidler, L. Albitar et al., “Tyrosine kinase inhibitors in endometrial cancer,” International Journal of Gynecological Cancer, vol. 15, no. 2, pp. 409–411, 2005. View at Publisher · View at Google Scholar
  99. H. Niikura, H. Sasano, G. Matsunaga et al., “Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma,” Human Pathology, vol. 26, no. 8, pp. 892–896, 1995. View at Google Scholar · View at Scopus
  100. P. Athanassiadou, E. Petrakakou, A. Liossi et al., “Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium,” Acta Cytologica, vol. 43, no. 6, pp. 1039–1044, 1999. View at Google Scholar · View at Scopus
  101. E. S. Gershtein, L. B. Bocharova, V. D. Ermilova, K. P. Laktionov, and Kushlinskiĭ, “Epidermal growth factor receptors and their ligands in endometrial carcinoma: correlation with clinico-morphologic factors and steroid receptors,” Voprosy Onkologii, vol. 46, no. 2, pp. 180–186, 2000. View at Google Scholar · View at Scopus
  102. M. A. Khalifa, R. S. Mannel, S. D. Haraway, J. Walker, and K.-W. Min, “Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas,” Gynecologic Oncology, vol. 53, no. 1, pp. 84–92, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. N. Nagai, T. Oshita, T. Fujii, H. Kioka, Y. Katsube, and K. Ohama, “Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer,” Oncology Reports, vol. 7, no. 3, pp. 551–559, 2000. View at Google Scholar · View at Scopus
  104. A. M. Oza, E. A. Eisenhauer, L. Elit et al., “Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4319–4325, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. G. E. Konecny, L. Santos, B. Winterhoff et al., “HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer,” British Journal of Cancer, vol. 100, no. 1, pp. 89–95, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. T. A. Grushko, V. L. Filiaci, A. J. Mundt, K. Ridderstråle, O. I. Olopade, and G. F. Fleming, “An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study,” Gynecologic Oncology, vol. 108, no. 1, pp. 3–9, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. G. Fleming, M. Sill, J. Thigpen et al., “Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: a report on GOG 181B,” in Proceedings of the 39th Annual Meeting American Society for Clinical Oncology, vol. 22, p. 453, Chicago, Ill, USA, May-June 2003.
  108. A. A. Kamat, W. M. Merritt, D. Coffey et al., “Clinical and biological significance of vascular endothelial growth factor in endometrial cancer,” Clinical Cancer Research, vol. 13, no. 24, pp. 7487–7495, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. D. S. McMeekin, M. W. Sill, D. Benbrook et al., “A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study,” Gynecologic Oncology, vol. 105, no. 2, pp. 508–516, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. J. D. Wright, M. A. Powell, J. S. Rader, D. G. Mutch, and R. K. Gibb, “Bevacizumab therapy in patients with recurrent uterine neoplasms,” Anticancer Research, vol. 27, no. 5, pp. 3525–3528, 2007. View at Google Scholar · View at Scopus
  111. H. S. Nimeiri, A. M. Oza, R. J. Morgan et al., “Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma(CS): a phase II trial of the University of Chicago, PMH, and California Phase II Consortia,” Journal of Clinical Oncology, vol. 26, 2008, ASCO Annual Meeting Proceedings (Post-Meeting Edition). View at Google Scholar
  112. S. A. Byron and P. M. Pollock, “FGFR2 as a molecular target in endometrial cancer,” Future Oncology, vol. 5, no. 1, pp. 27–32, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. M. Katoh, “FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies,” Journal of Investigative Dermatology, vol. 129, no. 8, pp. 1861–1867, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. M. Katoh, “Cancer genomics and genetics of FGFR2 (Review),” International Journal of Oncology, vol. 33, no. 2, pp. 233–237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. P. M. Pollock, M. G. Gartside, L. C. Dejeza et al., “Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes,” Oncogene, vol. 26, no. 50, pp. 7158–7162, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. S. A. Byron, M. G. Gartside, C. L. Wellens et al., “Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation,” Cancer Research, vol. 68, no. 17, pp. 6902–6907, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  117. S. A. Byron, M. G. Gartside, C. J. Wellens et al., “Correction: inhibition of activated FGFR2 in endometrial cancer,” Cancer Research, vol. 68, no. 23, article 10005, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. G. Sobel, J. Nemeth, A. Kiss et al., “Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma,” Gynecologic Oncology, vol. 103, no. 2, pp. 591–598, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. G. E. Konecny, R. Agarwal, G. A. Keeney et al., “Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer,” Gynecologic Oncology, vol. 109, no. 2, pp. 263–269, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. X. Y. Pan, B. Wang, Y. C. Che, Z. P. Weng, H. Y. Dai, and W. Peng, “Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue,” International Journal of Gynecological Cancer, vol. 17, no. 1, pp. 233–241, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. A. D. Santin, S. Bellone, M. Marizzoni et al., “Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE),” Cancer, vol. 109, no. 7, pp. 1312–1322, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus